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oughly 100 pharmaceuticals have now
been identified in rivers, lakes, and
coastal waters throughout Europe and
the United States in concentrations of parts per
billion to parts per trillion. The first major
European studies on this topic—in journals such
as volume 67, issue 1–4 (1997) of the Inter-
national Journal of Environmental Analytical
Chemistry and the November 1998 issue of
Water Research—examined German ground and
surfaces waters, and found occurrences of drugs
including cholesterol regulators, analgesics, and
antiseizure medications. Since that time, numer-
ous other studies have documented the presence
of pharmaceuticals, including potential
endocrine disruptors, in other locales as well. 
So far there is no evidence of adverse human
health effects due to traces of pharmaceuticals in
water. But scientists have linked certain pharma-
ceuticals with disturbing ecosystem changes. For
example, in volume 8 (1994) of Chemistry and
Ecology, researchers demonstrated that the femi-
nization of fish—male carp and trout producing
vitellogenin, an egg protein usually found only in
females—was associated with exposure to sewage
effluent now known to contain ethinyl estradiol,
the active ingredient in birth control pills. 
There is much concern about what is not
known: ecotoxicity data are available for less that
1% of human pharmaceuticals, according to esti-
mates published in the April 2004 issue of
Regulatory Toxicology and Pharmacology. Today,
intensive research is under way to investigate the
effect of human medications on the environment. 
In 1999, in response to these concerns, the
European Medicines Agency (EMEA) began
drafting guidance that outlined an environmen-
tal risk assessment procedure to accompany
pharmaceutical companies’ applications to mar-
ket new drugs in Europe. The latest draft was
published in January 2005, after several revi-
sions, and the public comment period closed in
April 2005. Scientists and pharmaceutical com-
panies alike hope the guidance will be finalized
later this year. 
The proposed European guidance is the first to
recommend long-term ecotoxicity testing for
environmental risk assessment of pharmaceuticals
from the outset of the proposed testing program
(in contrast, U.S. Food and Drug Administration
[FDA] requirements for chronic ecotoxicity test-
ing come later in that agency’s assessment). The
European guidance is also the first to take into
account the possibility of environmental effects
from extremely low concentrations of bioactive
substances, such as endocrine disruptors. 
If finalized, the guidance could call for sub-
stantially more testing of new drugs than has been
demanded thus far. Its implementation would
also generate much-needed chronic ecotoxicity
data. “The main advance in this draft guideline is
that we really address this issue and get more
information on the toxicity of these compounds,”
says Thomas Heberer, an environmental chemist
at the Technical University of Berlin and coauthor
of many papers on the topic, including the 1997
International Journal of Environmental Analytical
Chemistry report. 
What the Draft Guidance Covers
The draft guidance outlines the risk assessment
procedure for new active pharmaceutical sub-
stances, their metabolites, and possibly excipients
(the inert substances in which a drug is deliv-
ered) if they are deemed similar to chemicals with
known adverse environmental effects. It does not
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Damming the Flow 
of Drugs into Drinking Waterapply to drugs already on the market. If an
environmental risk is found, the guidance
recommends that the manufacturer take
appropriate precautionary and safety mea-
sures to limit the product’s environmental
impact. The guidance specifically recom-
mends the labeling of pharmaceuticals when
there is a possibility of an environmental
risk, to educate people about how best to
dispose of expired or unused medicines.
The guidance applies only to potential
environmental risks that are a consequence of
people storing, taking, and excreting medi-
cines. The potential risks posed by the manu-
facture of drugs are not addressed, nor does
the guidance apply to “orphan” drugs used
only to treat rare diseases. Separate guidance
governs medicinal products containing genet-
ically modified organisms. 
Proposed EMEA Protocols
The EMEA risk assessment protocol is a
tiered process that begins with a rough cal-
culation of the aquatic predicted environ-
mental concentration (PEC) of the new
drug. During this Phase I prescreening,
substances whose PEC is deemed too low
to be of concern to environmental health
are ruled out for further assessment.
Vitamins, electrolytes, amino acids, pep-
tides, and proteins are exempted by the
guidance because they are not tailored
active ingredients (unlike, for example, a
drug that interacts with a receptor) and
thus are deemed “unlikely to result in sig-
nificant exposure of the environment.”
However, the guidance does note that cer-
tain substances that are likely to cause
effects at very low concentrations, such as
endocrine disruptors, may need to be
addressed regardless of the quantity released
into the environment. 
Phase II begins with Tier A testing,
which aims to determine the aquatic fate
and effects of the drug. Its degradability,
potential to bioaccumulate, adsorption on
sewage sludge, and toxicity to sewage micro-
bial populations are evaluated from the
results of standard tests also used in the
FDA risk assessment. Also included in Tier
A of the EMEA protocol is the long-term
testing of fish, Daphnia (water fleas), and
algae to assess the predicted “no effect” con-
centration (PNEC) of the new drug for each
of these species. The PEC is further refined
at this stage in the EMEA assessment by tak-
ing into account the pharmaceutical compa-
ny’s projected sales forecast for the drug. 
The risk assessment is terminated if the
outcome of Tier A testing results in a PEC
lower than the PNEC. However, if the PEC
is greater than the PNEC in either water, sed-
iment, the sewage treatment plant, or soil
(where sewage sludge has been spread as a fer-
tilizer), this indicates a potential risk, and fur-
ther Tier B testing is initiated. These tests fol-
low the protocol in the European Technical
Guidance Document to further investigate the
risk posed by the drug to the environment.
For instance, where there is a potential risk to
soil, tests would be conducted to determine
the drug’s biodegradation in soil, its toxicity
to soil invertebrates, and its acute effects on
plants and soil microorganisms.
At this stage, data on the drug metabo-
lism and excretion profile may be consulted
to allow a more accurate calculation of the
PEC and determine whether metabolites
need to be tested. The EMEA guidance
recommends that metabolites exceeding
10% of the drug residue should be assessed
for environmental risk. If this round of
testing indicates that the PEC of the drug
will be greater than the PNEC, then phar-
maceutical companies following the
European approach must propose recom-
mendations to limit the drug’s impact on
the environment.
There are two major differences between
the proposed EMEA approach and the exist-
ing FDA approach. First, the FDA protocol
turns to chronic testing only if acute testing
indicates a risk or if there is an indication
that the drug could bioaccumulate. The lat-
est scientific research suggests that acute test-
ing is not a reliable indicator of all chronic
effects, however, and the EMEA document
reflects this finding. 
Second, the trigger concentrations of
pharmaceuticals that prompt risk assessment
under the FDA and EMEA guidance differ
by a factor of 10 when dilution is taken into
account. “The way the two guidelines express
this trigger may be confusing,” says Virginia
Cunningham, director of environmental sus-
tainability sciences for GlaxoSmithKline. She
explains that the EMEA’s trigger of 0.01
microgram per liter (µg/L) reflects a surface
water concentration, whereas the FDA’s 1.0
µg/L trigger reflects an “expected introduc-
tion concentration,” or the concentration of
a compound in sewage effluent.
The EMEA trigger of 0.01 µg/L is calcu-
lated from the maximum daily dose of the
drug per patient and the assumption that 1%
of the population is treated daily with the
drug; this is divided by the amount of waste-
water per person per day and a dilution fac-
tor of 10. The FDA trigger corresponds to a
PEC in surface water of 0.1 µg/L, assuming a
dilution factor of 10, and is calculated from
manufacturers’ sales estimates. 
The consideration given to metabolites
and the provision for the introduction of
scientific experts into the risk assessment
process—both part of the revisions to the
2003 guidance—are welcomed by scientists.
“It allows for experts to be drawn into the
discussion and give their opinions rather
than be sticking blindfolded to a number,”
says Evelyn O’Brien, a scientist in the
Ecotoxicology Workgroup at the University
of Konstanz in Germany and coauthor of a
discussion of the draft guideline published
in the July 2004 Trends in Biotechnology. 
One caution added by zoologist Theo
Colborn, whose seminal 1996 work Our
Stolen Future uncovered the dangers of
endocrine disruptors in the environment, is
that conflict of interests for experts working
in academia but funded by drug companies
must be revealed. “The important thing is,”
she says, “that in [the United States] they’re
selecting experts to do things like this on cam-
puses where the particular department that
that individual is working in oftentimes
receives tremendous amounts of grant money
from the pharmaceutical company. Openly
admitting conflict of interest is so important.” 
The EMEA website notes that members
of the agency’s scientific committees “are not
permitted to have any direct financial or
other interests in the pharmaceutical indus-
try. . . . They are required to make an annual
declaration of their financial interests and also
any indirect interests which could relate to
the pharmaceutical industry.” Colborn also
hails the guidance for including excipients as
well as active ingredients in the risk assess-
ment process. For instance, phthalates such as
diethyl phthalate and dibutyl phthalate, used
as plasticizers in the coating of some site-
directed drugs, may be a potential source of
phthalates for people taking these drugs, as
reported in the May 2004 issue of EHP.
Limitations of the Guidance
There are certain serious, though perhaps
unavoidable, limitations to the guidance.
One is the fact that they are not retroac-
tive. “The only thing that [researchers] are
concerned about is that the guidance only
concerns those pharmaceuticals that are
not yet on the market,” says Heberer. “It’s
our main concern about this guideline, but
compared to the situation in the past it’s
really an advance.” But even if future legis-
lation required the environmental risk
assessment of drugs already on the market,
the big question would be who should do
the testing since the originator of a drug is
often no longer the main manufacturer. 
Another major problem is that monitor-
ing may be difficult. “There are problems
detecting certain substances that have been
on the market for years,” says O’Brien.
Examples of such hard-to-detect drugs
include the antidepressants known as selec-
tive serotonin reuptake inhibitors (which
include Paxil, Prozac, and Zoloft). “So the
analysis can be quite difficult,” she says, “and
that’s one of the main stumbling features.”
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pose risks will be handled, apart from the
addition of labels to recommend appropriate
disposal of expired drugs. Another emerging
area of concern in North America and Europe
alike is the disposal of used birth control
patches and hormone replacement patches.
Because pharmaceuticals can save lives, the
guidance does not suggest removing them
from the market even when a risk is found. 
“I think there’s going to be a lot of
emphasis on labeling, and also on treatment
processes,” says Alistair Boxall, a senior lectur-
er at York University and Central Science
Laboratory in England. “So perhaps if you’ve
got a hospital where cancer drugs are being
used, it may be that we have to start putting
treatment processes on the end of the [sewer]
pipes of those hospitals to remove some of
the drugs.” 
Drug take-back programs for expired
pharmaceuticals are in place in parts of
Europe, so labeling drugs with instructions
to return unused portions to a pharmacy
makes sense. By comparison, in the United
States, the Controlled Substances Act
complicates such schemes because it pro-
hibits patients from transferring controlled
medicines to anyone other than a law
enforcement official. However, a drug
return program has recently been legislated
(though not implemented) in Maine. 
Another limitation, also difficult to
avoid, is that the draft guidance only briefly
addresses the possibility of additive or syner-
gistic effects, noting that an assessment fac-
tor of 10 is applied to the PNEC to account
for extrapolation from lab data to field
impacts. “It’s worth pointing out that the
guidance is written as if the concern is for a
single drug in isolation,” says Christian
Daughton, chief of the environmental chem-
istry branch at the Environmental Protection
Agency National Exposure Research Lab-
oratory. “But if a drug shares a common
mechanism of action with other drugs, or
even other pollutants, there’s the possibility
for additive effects.” 
Some scientists and drug companies are
concerned that assumptions in the guidance
could lead to unrealistic PECs. The initial cal-
culation assumes the worst-case scenario: that
the drug is not metabolized or degraded at all,
so the full dose ends up in the environment
(this is one of 30 points raised by the
Pharmaceutical Research and Manufacturers
of America in their comments on the guid-
ance). But others worry that actual concentra-
tions in the environment could be higher
than the calculated PEC due to the guidance’s
assumed 1:10 dilution factor for sewage efflu-
ent entering rivers. In farming areas, water
levels drop precipitously in dry weather when
water is drawn for crops and cattle, so the
1:10 dilution factor could be too high.
Colborn, a Colorado resident, says, “Most of
the river water that’s in this part of the West
is coming from returned sewage treatment
plants.” O’Brien argues the same point in
cities where the influx of people stretches the
capacity of sewage treatment plants. 
Another problem noted by O’Brien is
that peak or seasonal variations are not
taken into account—flu epidemics,
drought, or heavy snowfall could temporar-
ily increase drug concentrations in specific
places to values higher than the calculated
PEC. Colborn also comments that local use
of pharmaceuticals differs, reflecting, for
example, recent visits by pharmaceutical
representatives telling doctors about new
drugs. “To estimate that pharmaceuticals
will be released homogeneously across a
particular region is, I think, mistaken,” she
says. Daughton addressed these and related
issues in greater detail in the May 2003
issue of EHP.
One worry for pharmaceutical compa-
nies is that the increased amount of testing
required could translate into costly delays
for the release of new drugs. About 50 new
drugs come onto the market in the United
States each year, and approximately a dozen
of those are predicted to occur above the
trigger concentration requiring them to
undergo the first level, or Tier A, of risk
assessment testing. 
But only one new drug in the last few
years has gone on to the next level to be test-
ed for environmental risks through chronic
ecotoxicity tests, according to Florian
Zielinski, a chemist at the FDA Center for
Drug Evaluation and Research. “In fact, in
the States, almost all pharmaceuticals in the
Tier A assessment will come out at under one
microgram per liter,” says Chris Metcalfe, a
professor in the Environmental and Resource
Studies Program at Trent University in
Ontario, “whereas in the EU there will be a
fair number of pharmaceuticals which will
move from the Tier A to the Tier B as a
result of their lower thresholds.” British labs
put about 20 new pharmaceutical products
on the market each year.
Forging Ahead
Since neither the EMEA guidance nor its
U.S. sister document addresses pharmaceu-
ticals already on the market, there is much
research into whether wastewater treat-
ment can economically remove pharma-
ceuticals. Increased retention time within
treatment plants, chlorination, ozonation,
and the natural reduction of a compound’s
mass or concentration over time due to
processes such as biodegradation all
increase the removal of some drugs from
wastewater; more advanced treatments
such as adding activated carbon or reverse
osmosis can remove even more. “But
there’s never a silver bullet,” says Shane
Snyder, research and development project
manager of the Southern Nevada Water
Authority. “There’s always a catch.” 
The catch with ozone treatment is that it
forms bromate, which is a regulated disin-
fection by-product; with chlorination, the
catch is that chlorine combines with ammo-
nia in the sewage treatment system to form
chloramines, which are not strong oxidants
and so cannot break down compounds such
as estrogens. However, chlorination can
destroy almost all the estrogens if ammonia
is removed first, says Snyder. But even with
the use of reverse osmosis (which removes
pharmaceuticals down to parts per trillion)
and the addition of activated carbon, there’s
the problem of what to do with the retained
contaminants. 
Although Europe has been at the fore-
front of recognizing and addressing the
potential environmental hazard posed by
pharmaceuticals, other countries are perhaps
beginning to catch up. In the United States,
for example, the Federal Interagency Task
Group on Pharmaceuticals and Personal
Care Products was formed in September
2004. This group comprises seven federal
agencies and is chaired by the FDA. The
group had its first face-to-face meeting in
July 2005 to identify federal research needs
and gaps. One of the questions raised was
how much of the estrogen in wastewater
comes from synthetic sources. 
In Canada, the Environmental Impact
Initiative was formed in 2001 in response to
growing evidence that pharmaceutical sub-
stances are being found in the environment.
The initiative, which accepted public com-
ments through September 2005 on proposed
options for regulating these substances, may
result in new rules for the environmental
assessment of substances in products regulat-
ed under the Food and Drugs Act, according
to Health Canada. Japan is also in the process
of formulating a plan for environmental risk
assessment of pharmaceuticals with sales
exceeding one ton per year.
In the meantime, the EMEA draft guid-
ance is seen as an appropriate response to an
emerging issue which includes possible risks
not just from pharmaceuticals but also from
personal care products. “What has come
into the scientific literature is that most
pharmaceuticals do not show acute ecotoxic-
ity, so the whole mindset is shifting to
chronic toxicity, and I think the EMEA
guideline is trying to reflect that,” says
Cunningham. “None of the people I talk to
have a problem with that.”
Pat Hemminger
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